home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Diamond Collection
/
The Diamond Collection (Software Vault)(Digital Impact).ISO
/
cdr16
/
med9505a.zip
/
M9550112.TXT
< prev
next >
Wrap
Text File
|
1995-03-04
|
2KB
|
35 lines
Document 0112
DOCN M9550112
TI Interspecies scaling and pharmacokinetic parameters of 3TC in humans.
DT 9505
AU Hussey EK; Donn KH; Daniel MJ; Hall ST; Harker AJ; Evans GL; Glaxo Inc.
Research Institute, Research Triangle Park, North; Carolina 27709.
SO J Clin Pharmacol. 1994 Oct;34(10):975-7. Unique Identifier : AIDSLINE
MED/95138293
AB 3TC is a dideoxy-nucleoside analogue that has demonstrated in-vitro
activity against human immunodeficiency virus (HIV). 3TC concentrations
in humans were predicted before the initiation of clinical trials by
interspecies scaling of pharmacokinetic parameters observed in animal
species. Clearance and volume of distribution were estimated for humans
using linear regression on a log-log scale of each parameter versus body
weight for rats and dogs. The concentration-time profile and the average
serum concentration at steady state after various dosage regimens were
estimated as a basis for initial dose selection for clinical trials. The
predicted parameters (clearance of 16.3 L/hr and volume of distribution
of 40 L for a 70-kg man) were compared with that observed (mean
clearance of 24 L/hr and mean volume of distribution of 96 L, mean
weight of 74 kg) in 20 asymptomatic, HIV positive, volunteers after
single intravenous doses of 3TC. Interspecies scaling was applied
prospectively as a rationale for dose selection of 3TC in clinical
trials.
DE Animal Antiviral Agents/ADMINISTRATION & DOSAGE/*PHARMACOKINETICS Body
Weight/PHYSIOLOGY Comparative Study Cross-Over Studies
Cytosine/*ANALOGS & DERIVATIVES/ADMINISTRATION & DOSAGE/
PHARMACOKINETICS Dogs Human HIV Seropositivity/METABOLISM Infusions,
Intravenous Male Rats Reverse Transcriptase/*ANTAGONISTS & INHIB
Species Specificity CLINICAL TRIAL JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).